Concept
Ligand binding assay
Related publications (74)
Antibodies expand the scope of angiotensin receptor pharmacology
Patrick Daniel Barth, Shuhao Zhang
G-protein-coupled receptors (GPCRs) are key regulators of human physiology and are the targets of many small-molecule research compounds and therapeutic drugs. While most of these ligands bind to their target GPCR with high affinity, selectivity is often l ...
2024Improved antibody pharmacokinetics by disruption of contiguous positive surface potential and charge reduction using alternate human framework
Andrea Pfeifer, Florence Gauye, Tariq Afroz, Monisha Ratnam
Optimal pharmacokinetic (PK) properties of therapeutic monoclonal antibodies (mAbs) are essential to achieve the desired pharmacological benefits in patients. To accomplish this, we followed an approach comprising structure-based mAb charge engineering in ...
TAYLOR & FRANCIS INC2023Systematic analysis of biomolecular binding reactions using microfluidic systems
Transcription factor binding to a single binding site on DNA and its functional consequence in a promoter context are beginning to be relatively well understood. However, binding to clusters of sites has yet to be characterized in depth, and the functional ...
EPFL2022Novel trehalose-based excipients for stabilizing nebulized anti-SARS-CoV-2 antibody
Sandrine Gerber, François Rémi Pierre Noverraz, Solène Marcelle Françoise Marie Passemard
COVID-19 is caused by the infection of the lungs by SARS-CoV-2. Monoclonal antibodies, such as sotrovimab, showed great efficiency in neutralizing the virus before its internalization by lung epithelial cells. However, parenteral routes are still the prefe ...
2022Computational rewiring of allosteric pathways reprograms GPCR selective responses to ligands
Patrick Daniel Barth, Mahdi Hijazi, Aurélien Laurent Jean-Charles Oggier, Dániel Kéri
G-protein-coupled receptors (GPCRs) are the largest class of cell surface receptors and drug targets, and respond to a wide variety of chemical stimuli to activate diverse cellular functions. Understanding and predicting how ligand binding triggers a speci ...
bioRxiv2022Pharmacological characterization of mutant huntingtin aggregate-directed PET imaging tracer candidates
Huntington's disease (HD) is caused by a CAG trinucleotide repeat expansion in the first exon of the huntingtin (HTT) gene coding for the huntingtin (HTT) protein. The misfolding and consequential aggregation of CAG-expanded mutant HTT (mHTT) underpin HD p ...
NATURE PORTFOLIO2021Structural Basis of Ligand Selectivity by a Bacterial Adhesin Lectin Involved in Multispecies Biofilm Formation
Carbohydrate recognition by lectins governs critical host-microbe interactions. MpPA14 (Marinomonas primoryensis PA14 domain) lectin is a domain of a 1.5-MDa adhesin responsible for a symbiotic bacterium-diatom interaction in Antarctica. Here, we show that ...
Washington2021Alpha-Synuclein oligomerization and aggregation: All models are useful but only if we know what they model This is the reply to a comment "Alpha-synuclein oligomerization and aggregation: A model will always be a model" on the original article "Monitoring alpha-synuclein oligomerization and aggregation using bimolecular fluorescence complementation assays: What you see is not always what you get". The articles are accompanied by a Preface "How good are cellular models?".
Alpha-synuclein oligomerization is one of the early events on the pathway to Lewy body formation. Therefore, interfering with this process holds tremendous potential for developing therapies that block alpha-Syn pathology formation and toxicity. The develo ...
WILEY2021Targeting the oncogenic signaling of the transcription factor STAT3 with potent and selective monobody inhibitors
Many targeted cancer therapies fail to improve the overall survival of patients. Limitations involve low drug selectivity and the rapid development of resistance. Moreover, the majority of oncogenic drivers presently remain considered as undruggable as th ...
EPFL2020An optimized and validated 384-well plate assay to test platelet function in a high-throughput screening format
Nikolaos Stergiopoulos, Olivier Burri, Marc Chambon, Julien Bortoli Chapalay, Fabiana Pereira Da Costa Fraga, Augusto Martins Lima, Maiia Bragina
Despite significant advances in the treatment of cardiovascular diseases, antiplatelet therapies are still associated with a high risk of hemorrhage. In order to develop new drugs, methods to measure platelet function must be adapted for the high-throughpu ...
TAYLOR & FRANCIS INC2019